vimarsana.com
Home
Live Updates
Hemab Therapeutics Presents New Preclinical Research Demonstrating Effects of Its Bispecific Antibody HMB-001 in Factor VII Deficiency : vimarsana.com
Hemab Therapeutics Presents New Preclinical Research Demonstrating Effects of Its Bispecific Antibody HMB-001 in Factor VII Deficiency
/PRNewswire/ -- Hemab Therapeutics, a clinical-stage biotechnology company developing the first prophylactic therapeutics for serious, underserved bleeding and...
Related Keywords
Montreal ,
Quebec ,
Canada ,
Denmark ,
Copenhagen ,
Køavn ,
Boston ,
Massachusetts ,
United States ,
Viia Fviia ,
Glanzmann Thrombasthenia ,
Benny Sorensen ,
International Society On Thrombosis ,
European Association For Haemophilia ,
International Society ,
Demonstrates Effect ,
European Association ,
Allied Disorders ,
Bernard Soulier Syndrome ,
Von Willebrand Disease ,
Hemab Therapeutics ,
vimarsana.com © 2020. All Rights Reserved.